GSK reports PhIII flop for BCMA drug — raising questions about its future and upping the stakes on combos
Two years after an accelerated approval, GSK’s BCMA-targeting antibody-drug conjugate has flunked a Phase III study in multiple myeloma, raising doubts about the pharma giant’s plan to move it up to earlier lines of treatment.
The Monday update comes from DREAMM-3, a head-to-head trial pitting GSK’s Blenrep against PomDex, the standard-of-care combo of the chemotherapy pomalidomide and the steroid dexamethasone. Blenrep failed the primary endpoint of progression-free survival.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
